Table 2.
Patient | Case | Publication (Year) | Age | Sex | Underlying Conditions | Immunosuppressants | Antiviral Treatment | Infection Length, Days | Fatal? |
---|---|---|---|---|---|---|---|---|---|
Pe1 | Choi et al [8] | New Engl J Med (2020) | 45 | M | Antiphospholipid antibody syndrome | Rituximab, eculizumab, cyclophosphamide, corticosteroids | Remdesivir, casirivimab and imdevimab | 154 | Yes |
Pe2 | Baang et al [10] | J Infect Dis (2021) | 60 | M | Refractory mantle cell lymphoma | CD20 bispecific Ab, B-cell directed Ab, cyclophosphamide, doxorubicin, prednisone | Remdesivir, convalescent plasma | 156 | Yes |
Pe3 | Avanzato et al [9] | Cell (2020) | 71 | F | CLL, acquired hypogammaglobulinemia | … | Convalescent plasma | 156 | No |
Pe4 | Kemp et al [11] | Nature (2021) | … | … | Marginal B-cell lymphoma, hypogammaglobulinemia | B-cell–depleting therapy | Remdesivir, convalescent plasma | 102 | Yes |
Pe5 | Tarhini et al [27] | J Infect Dis (2021) | 66 | M | HIV, multifocal leukoencephalopathy from JC virus | … | … | 124 | No |
Pe6–1 | TTruong et al [28] | EBioMedicine (2021) | <5 | F | B-cell ALL | Dexamethasone, vincristine, peg- asparaginase, methotrexate, 6-MP, doxorubicin | … | 91 | No |
Pe6–2 | 20–25 | M | B-cell ALL | CD-19–directed CAR-T cell therapy (tisagenlecleucel), cylcophosphamide, fludarabine | Remdesivir, convalescent plasma | 250+ | No | ||
Pe6–3 | <5 | M | B-cell ALL | Cyclophosphamide, cytarabine, thioguanine, vincristine, dexamethasone, methotrexate, mercaptopurine | … | 196 | No | ||
Pe7 | Borges et al [29] | Virological | 61 | F | Diffuse large B-cell lymphoma | Chemotherapy (unspecified), methotrexate, corticosteroids | Remdesivir | 197 | No |
Abbreviations: Ab, antibody; ALL, acute lymphoblastic leukemia; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; F, female; HIV, human immunodeficiency virus; JC virus, John Cunningham virus; J Infect Dis, Journal of Infectious Diseases; M, male; New Engl J Med, New England Journal of Medicine.